The world's first PD-1/VEGF bispecific antibody:ivonescimab
- VernacularTitle:全球首个PD-1/VEGF双特异性抗体:依沃西单抗
- Author:
Caihong SUN
1
;
Taotao HU
1
;
Xingxing XIAO
1
;
Mengnan YUAN
1
;
Simin JIANG
1
;
Yinqi CHEN
1
;
Guodong RUAN
1
Author Information
- Publication Type:Journal Article
- Keywords: ivonescimab; non-small cell lung can-cer; PD-1/VEGF; antineoplastic drug
- From: Chinese Journal of Clinical Pharmacology and Therapeutics 2025;30(9):1290-1296
- CountryChina
- Language:Chinese
- Abstract: Ivonescimab is a humanized bispecific antibody targeting human vascular endothelial growth factor-A(VEGF-A)and programmed death protein-1(PD-1).It was approved by National Medi-cal Products Administration on May 24th,2024,and can be used in combination with pemetrexed and carboplatin for locally advanced or positive EG-FR gene mutation after treatment with epidermal growth factor receptor(EGFR)tyrosine kinase inhib-itor.This paper mainly introduces the research progress of the world's first PD-1/VEGF bispecific antibody ivonescimab,and summarizes the mecha-nism of action,pharmacokinetics,phase Ⅰ-Ⅲ clinical trials and drug safety.
